Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
410 participants
OBSERVATIONAL
2021-05-05
2024-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will take place at multiple locations in the United States and Spain.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolomics Non Selection Study - Vitrolife Media
NCT04976920
Embryo Selection Using Non-invasive Metabolomic Analysis Versus Morphology
NCT01490515
Targeted Metabolomics and Spent Embryo Culture Medium
NCT06094439
ReceptIVFity & Immunology in ART
NCT06709976
The Microbiome of Infertile Couples and Its Effect on Their Reproductive Outcomes
NCT03420859
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis. Details of sample collection and analysis are provided in Sections 6.3.1 \& 6.3.2.
Single embryo transfer will be performed with the best morphology blastocyst being selected for transfer by the New Hope embryologist.
Approximately 8-11 days after the embryo transfer, the patient will return to the clinic for a serum pregnancy test. Should the test be negative, they will be closed out of the study. Should the test be positive, they will continue to be monitored.
The patient will return to the clinic at approximately 8 weeks after embryo transfer for a serum pregnancy test, and an ultrasound to detect fetal heartbeat. The outcome will be documented, and the patient monitored until 12 weeks of gestation at which time they will be closed from the study.
The embryo transfer outcome will be compared to MPI and MEI result to determine the NPV and PPV of metabolomics vs implantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Group
Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.
Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.
For the embryo transfer, the best morphology blastocyst will be selected for transfer by the study embryologist. The embryo transfer outcome will be compared to the Metabolomics result to determine the NPV and PPV of Metabolomics vs implantation.
Overture Metabolomics Embryo Selection
Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Overture Metabolomics Embryo Selection
Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed Subject Consent Form. No inferior limit on number of eggs
Exclusion Criteria
* Require or request PGT of any kind
* Low ovarian reserve defined as follicle stimulating hormone (FSH) \>10 IU/L on day 2-4 of a prior menstrual cycle and anti-mullerian hormone (AMH) \<15 pmol/L (or \<2 ng/ml) within prior 12 months of cycle start
At the time of embryo selection:
-Patients without at least one embryo to transfer.
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New Hope Fertility Center
OTHER
Clinica Juana Crespo
UNKNOWN
Overture Life
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Jose Horcajadas
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Horcajadas, PhD
Role: PRINCIPAL_INVESTIGATOR
Overture Life
Santiago Munne, PhD
Role: PRINCIPAL_INVESTIGATOR
Overture Life
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Hope Fertility Center
New York, New York, United States
Clinical Juana Crespo
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jose Teruel Lopez
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUB-OVL-IRB-MTB-06.01.2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.